Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

ys. 55(3), 707-12 (2003)).

The presentation slides are available at www.celltherapeutics.com/investor_updates.

CTI has an existing license and co-development agreement with Novartis for OPAXIO, which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015 BioElectronics Corporation (OTC ... Musculoskeletal Pain Therapy medical devices, announced today that ... ActiPatch 7-day trial device has been published in ... Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 ... submitted an assessment.  Chronic pain ...
(Date:8/4/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Animal Biotechnology - ... This report describes and evaluates animal ... pharmaceuticals as well as improvement in food production. ... application of biotechnology to manage genetic disorders and ...
(Date:8/4/2015)... Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX ),  a targeted oncology ... be presenting at the 2015 Wedbush PacGrow Healthcare Conference on ... PT) in New York . Charles ... will provide a corporate overview. A live audio ... page of Mirati,s corporate website at www.mirati.com . A ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... SPRING, Md., April 28, 2011 The U.S. ... acetate) in combination with prednisone (a steroid) to ... who have received prior docetaxel (chemotherapy). ... cancer, the male sex hormone testosterone stimulates prostate ...
... Sciences Inc. (PSI), a leading pharmaceutical CRO, and ... ethylene vinyl acetate (EVA) into pharmaceutical applications, are ... devices.  Building on years of collaboration, Particle Sciences ... provide Particle Sciences with preferred access to VitalDose™ ...
Cached Medicine Technology:FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 2Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... sweat. Evolutions Medical & Day Spa in Santa Barbara, CA is offering the ... cleared treatment that permanently eliminates sweat and odor glands in the underarms. This ...
(Date:8/4/2015)... ... August 04, 2015 , ... School is almost back in session. ... and preparing for the back-to-school scramble. Dublin, OH family dentist , Dr. Cheung ... for the annual dental checkup. In fact, the dentist recently updated the practice’s surgical ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... One of ... interviews to discuss his new book, The Pain Antidote , which provides strategies ... of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction ...
(Date:8/4/2015)... ... , ... 24/7 Care At Home , a provider of comprehensive home ... that the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating ... on the path to meeting the aspirational goals the VA promotes each year. ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... with “Dr. Google” before calling a physician. In an effort to share more ... health care provider in Pennsylvania to publicly share patient satisfaction ratings and comments ...
Breaking Medicine News(10 mins):Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... 21 countries, reserachers have found that blood pressure levels across ... not go down in all of the populations, but it ... led the World Health Organization MONICA study conducted between 1980s ... did appear to have a cross- population effect. Most importantly, ...
... overseas-trained doctor, Farid Zaer, who has registered himself as ... Queensland, to continue his medical practice.// The doctor has ... accused for wrong diagnosis involving nearly 208 patients. ... as a GP, without any restriction or supervision. Under ...
... African American children deteriorate as they progress through puberty, ... of Alberta//. The levels of insulin, however, remain unchanged ... phase of growth plays a crucial role in determining ... 7-year, Alabama based study was conducted by Dr. Geoff ...
... to tackle the global threat from bird flu, it ... is felt that// it may provide the best help ... up such a system has been published in the ... through co-ordination between such international labs can warn the ...
... pregnancy can reduce the incidence of pregnancy complications, ... by American Journal of Obstetrics and Gynecology. ... blood pressure and proteinuria (high levels of protein ... and legs is usually seen. If left unattended, ...
... In an attempt to spread awareness about AIDS/HIV, the ... the State organized a health awareness program// ('One step ... targeted specifically at barbers. ,The local barbers, ... rally. A special AIDS/HIV awareness session was conducted at ...
Cached Medicine News:Health News:Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered 2Health News:African American Children More Pone to Develop Diabetes 2
The Manual Table Base is elevated with an easy to reach elevating wheel for smooth operation. The table base will accept a slit lamp, a single table top, or a double tabletop for more than one instru...
... Ideal for satellite clinics or for ... value, the Debut stand is an ... construction and molded composite body offer ... counterbalanced slit-lamp arm--one of two arms ...
A new, innovative design compliments the proven, 30-year mechanical operating system....
The Encore Stand combines the proven mechanical structure and durability of the popular Deluxe Stand, with a modern, sophisticated appearance....
Medicine Products: